Orexin-A vs Ipamorelin
Head-to-head comparison of Orexin-A (Hypocretin-1 (Orexin-A)) and Ipamorelin (Growth Hormone Secretagogue) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Orexin-A | Ipamorelin |
|---|---|---|
| Category | Cognitive Enhancement | Performance |
| Full Name | Hypocretin-1 (Orexin-A) | Growth Hormone Secretagogue |
| Molecular Weight | 3562 Da | 711.85 Da |
| Half-Life | Minutes to <1 hour | ~2 hours |
| Amino Acids | 33 | 5 |
| Typical Dose | Research-only; no validated human dose | 200-300 mcg |
| Route | Intracerebroventricular/Intranasal | SC |
| Purity | ≥98% | — |
| Studies Count | 42 | 156 |
| Research Status | Pre-clinical | Clinical Trials |
Orexin-A Benefits
- ✓wakefulness
- ✓attention
- ✓memory consolidation
- ✓fatigue resistance
Ipamorelin Benefits
- ✓Stimulates natural GH release
- ✓Minimal cortisol/prolactin increase
- ✓Improved body composition
- ✓Enhanced recovery and sleep quality
- ✓Anti-aging effects
Orexin-A Dosing
Research-only i.c.v. microgram/nanomolar studies|intranasal experimental use|no established human protocol
Ipamorelin Dosing
Standard: 200-300 mcg SC 2-3 times daily|Pre-bed: 200 mcg SC 30 min before sleep|Combined: 100-200 mcg with CJC-1295 2-3x daily
Orexin-A Side Effects
- ⚠insomnia
- ⚠headache
- ⚠blood pressure changes
Ipamorelin Side Effects
- ⚠Common (Mild): Temporary tingling, water retention, increased appetite
- ⚠Rare: Headache, lightheadedness
- ⚠Very Well Tolerated overall
Research Overview
Orexin-A
Preclinical studies link orexin signaling to arousal, learning, and memory consolidation, making orexin-A a candidate for cognition-related research. It is not an approved cognitive enhancer and remains an experimental peptide.
Ipamorelin
Ipamorelin has moderate clinical evidence. Phase II trials demonstrate selective GH release. Generally regarded as one of the safest GH secretagogues with minimal side effect profile.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.